Clinical Trial Update: A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating the safety and tolerability of subcutaneous MEDI-545 in subjects with systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• MEDI-545

Snippet

Sponsor: MedImmune LLC | Conditions: Lupus Erythematosus, Systemic, Lupus | Phase 2 | Status: COMPLETED